Merus assumed with a Buy at Guggenheim. Guggenheim analyst Michael Schmidt assumed coverage of Merus with a Buy rating and $25 price target. The company has a “differentiated” bispecific antibody platform with rapid target screening and lead optimization technology, Schmidt tells investors in a research note. The analyst sees multiple clinical catalysts for the company through the second half of 2019 and “considerable potential upside to valuation if any single program is successful.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.